Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 17473201)

1.

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM.

Clin Cancer Res. 2007 May 1;13(9):2692-8.

2.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.

Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review.

3.

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

Font A, Sanchez JM, Rosell R, Taron M, Martinez E, Guillot M, Manzano JL, Margeli M, Barnadas A, Abad A.

Lung Cancer. 2002 Aug;37(2):213-8. Review.

PMID:
12140145
4.

Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.

Belani CP; TAX 326 Study Group.

Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. Review.

PMID:
12170445
5.

Docetaxel in combination chemotherapy for metastatic breast cancer.

Khayat D, Antoine E.

Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-19-S13-26. Review.

PMID:
9335513
6.
7.

Phase I trials of pemetrexed.

Fossella FV, Gatzemeier U.

Semin Oncol. 2002 Apr;29(2 Suppl 5):8-16. Review.

PMID:
12023787
8.

Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.

Shimanovsky A, Dasanu CA.

Expert Opin Pharmacother. 2013 Mar;14(4):515-23. doi: 10.1517/14656566.2013.770474. Epub 2013 Feb 14. Review.

PMID:
23409799
9.

Preclinical pharmacology of the taxanes: implications of the differences.

Gligorov J, Lotz JP.

Oncologist. 2004;9 Suppl 2:3-8. Review.

10.

Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.

Foss FM.

Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1141-52. doi: 10.1517/17425255.2011.595404. Epub 2011 Jul 5. Review.

PMID:
21726160
11.

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

Parker T, Barbarotta L, Foss F.

Future Oncol. 2013 Jan;9(1):21-9. doi: 10.2217/fon.12.168. Review.

PMID:
23252560
12.

The taxanes: toxicity and quality of life considerations in advanced ovarian cancer.

Guastalla JP 3rd, DiƩras V.

Br J Cancer. 2003 Dec;89 Suppl 3:S16-22. Review.

13.

Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?

Schwartz JR.

J Oncol Pharm Pract. 2012 Jun;18(2):250-6. doi: 10.1177/1078155211409473. Epub 2011 Aug 1. Review.

PMID:
21807762
14.

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.

Chiuri VE, Silvestris N, Lorusso V, Tinelli A.

Curr Drug Targets. 2009 Oct;10(10):982-1000. Review.

PMID:
19663766
15.

Taxanes in the elderly: can we gain as much and be less toxic?

Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A.

Crit Rev Oncol Hematol. 2009 Jun;70(3):262-71. doi: 10.1016/j.critrevonc.2008.07.017. Epub 2008 Aug 30. Review.

PMID:
18762431
16.

Defining risks of taxane neuropathy: insights from randomized clinical trials.

Kudlowitz D, Muggia F.

Clin Cancer Res. 2013 Sep 1;19(17):4570-7. doi: 10.1158/1078-0432.CCR-13-0572. Epub 2013 Jul 1. Review.

17.

Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.

Raisch DW, Campbell W, Garg V, Qureshi ZP, Bookstaver PB, Norris LB, Bennett CL.

Expert Opin Drug Saf. 2011 Jul;10(4):521-8. doi: 10.1517/14740338.2011.582865. Epub 2011 May 20. Review.

PMID:
21595611
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk